Want to see IN:SENORES full AI Analyst Report?
Top Page
Senores Pharmaceuticals Ltd.
(SENORES)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹1,565.00
▲(118.30% Upside)
Action:Reiterated
Date:06/13/26
The score is driven primarily by strong reported FY2026 growth and profitability, tempered by persistently negative free cash flow and weak cash conversion. Technicals remain supportive with a strong uptrend, but overbought signals add near-term risk. A high P/E further limits the score due to valuation pressure.
Positive Factors
FY2026 Scale and Profitability
The sharp FY2026 increase in revenue alongside healthy gross, operating, and net margins indicates substantially stronger current earnings power. If these economics persist, greater scale can support reinvestment, strengthen market positioning, and provide a more durable base for future growth.
Negative Factors
Persistently Negative Free Cash Flow
Free cash flow remaining deeply negative despite much stronger reported profitability indicates that investment spending or working-capital demands are absorbing substantial cash. Persistent cash consumption can constrain reinvestment flexibility, increase funding needs, and weaken the durability of earnings quality.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 Scale and Profitability
The sharp FY2026 increase in revenue alongside healthy gross, operating, and net margins indicates substantially stronger current earnings power. If these economics persist, greater scale can support reinvestment, strengthen market positioning, and provide a more durable base for future growth.
Read all positive factors
Senores Pharmaceuticals Ltd. (SENORES) vs. iShares MSCI India ETF (INDA)
Market Cap
₹67.36B
Dividend YieldN/A
Average Volume (3M)15.71K
Price to Earnings (P/E)51.6
Beta (1Y)0.94
Revenue Growth51.74%
EPS Growth77.53%
CountryIN
Employees368
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)10.35
Shares Outstanding46,053,590
10 Day Avg. Volume16,221
30 Day Avg. Volume15,708
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.63
Price to Sales (P/S)5.35
P/FCF Ratio-16.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)34.4
Revenue Forecast (FY)₹9.07B
Senores Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Established in 2017 and headquartered in Ahmedabad, India, Senores Pharmaceuticals Ltd. is actively involved in the development, manufacturing, and global commercialization of pharmaceutical and related products. Its extensive portfolio reaches ma...
Senores Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2025 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 2.52B | 6.33B | 3.83B |
| Gross Profit | 1.29B | 3.81B | 14.11M |
| EBITDA | 849.50M | 2.15B | 1.08B |
| Net Income | 502.10M | 1.15B | 6.85M |
Balance Sheet | |||
| Total Assets | 12.88B | 16.04B | 145.66M |
| Cash, Cash Equivalents and Short-Term Investments | 3.60B | 3.32B | 3.85B |
| Total Debt | 2.41B | 3.42B | 3.15B |
| Total Liabilities | 4.54B | 6.39B | 50.70M |
| Stockholders Equity | 8.14B | 9.34B | 7.86B |
Cash Flow | |||
| Free Cash Flow | -2.27B | -2.03B | -2.03B |
| Operating Cash Flow | -280.86M | 620.50M | -459.20M |
| Investing Cash Flow | -3.34B | -1.21B | -4.29B |
| Financing Cash Flow | 4.39B | -13.30M | 5.73B |
Senores Pharmaceuticals Ltd. Technical Analysis
Positive
716.90
Price Trends
1430.35
Positive
1259.92
Positive
1028.01
Positive
Market Momentum
14.92
Positive
51.09
Neutral
61.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SENORES, the sentiment is Positive. The current price of 716.9 is below the 20-day moving average (MA) of 1487.40, below the 50-day MA of 1430.35, and below the 200-day MA of 1028.01, indicating a neutral trend. The MACD of 14.92 indicates Positive momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 61.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SENORES.
Senores Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹537.03B | 33.62 | ― | 2.08% | 6.29% | 11.18% | |
80 Outperform | ₹149.75B | 28.87 | ― | 0.27% | 19.59% | 47.58% | |
64 Neutral | ₹67.36B | 51.56 | ― | ― | 51.74% | 77.53% | |
56 Neutral | ₹39.25B | 41.23 | ― | 0.09% | 10.25% | 33.78% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹11.38B | 45.50 | ― | 1.27% | 11.96% | -28.48% |
* General Sector Average
IN:SENORES
Senores Pharmaceuticals Ltd.
1,467.45
778.60
113.03%
IN:ABBOTINDIA
Abbott India Limited
25,586.10
-4,670.34
-15.44%
IN:KOPRAN
Kopran Limited
235.55
60.47
34.54%
IN:MARKSANS
Marksans Pharma Limited
328.30
155.78
90.29%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,039.05
-1,077.45
-21.06%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
464.30
172.95
59.36%
Senores Pharmaceuticals Ltd. Corporate Events
Senores Pharmaceuticals Releases Q1 FY27 Earnings Call Transcript
Aug 3, 2026
Senores Pharmaceuticals Ltd. notified stock exchanges that it has released the official transcript of its Q1 FY27 earnings conference call, held on July 27, 2026. The document has been submitted under regulatory disclosure norms and is also availa...
Senores Pharmaceuticals Files Q1FY27 Investor Presentation With Indian Stock Exchanges
Jul 27, 2026
Senores Pharmaceuticals Limited has released its investor presentation for the first quarter of fiscal year 2027, following an earlier intimation of its earnings conference call. The presentation, now available on the company’s website and s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.